Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...
mTOR and tyrosine kinase inhibitors may play an increasing role in the management of well-differentiated neuroendocrine tumors in the future. Peptide receptor radiotherapy is a new treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback